Adjuvant Intravesical Chemotherapy in Patients with Primary T1 G3 Transitional Cell Carcinoma of the Bladder

1993 ◽  
Vol 60 (4) ◽  
pp. 345-348
Author(s):  
V. Serretta ◽  
S. Piazza ◽  
C. Pavone ◽  
G. Corselli ◽  
B. Piazza ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Transitional Cell Carcinoma ◽  
Carcinoma In Situ ◽  
Transitional Cell ◽  
Invasive Disease ◽  
Intravesical Chemotherapy ◽  
Carcinoma Of The Bladder ◽  
Bladder Tumours

The Authors present their experience with TUR plus adjuvant intravesical chemotherapy in 50 patients affected by primary T1 G3 bladder tumours without previous or concomitant carcinoma in situ. At a mean follow-up of 36 months, 84% of the patients are alive and tumour-free. Cystectomy was performed in three patients due to locally invasive disease. Five patients (10%) died of bladder cancer.

scholarly journals Does Urine Cytology Still have a Role?

2005 ◽  
Vol 72 (3) ◽  
pp. 301-306
Author(s):  
M. Ciaccia ◽  
R. Bertoloni ◽  
F. Pinto ◽  
A. Calpista ◽  
P.F. Bassi
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Carcinoma In Situ ◽  
Transitional Cell ◽  
High Sensitivity ◽  
Urine Cytology ◽  
Low Grade ◽  
New Methods

Urine cytology is a reliable and well known tool in the diagnosis and follow-up of patients with transitional cell carcinoma even if it has high sensitivity only in high grade tumors and carcinoma in situ. In order to improve sensitivity of this test in patients with low grade tumors, new methods such as cytometry, microsatellite assays, Immunocyt®, fuorescence in-situ hybridization and Thin-Prep monolayer have been developed. These new assays will be able to increase the cytology detection rate and to predict the outcome of transitional cell carcinoma.

MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER:

2000 ◽  
pp. 1124-1129 ◽  
Author(s):  
DONALD L. LAMM &NA; &NA; ◽  
BRENT A. BLUMENSTEIN ◽  
JOHN D. CRISSMAN ◽  
JAMES E. MONTIE ◽  
JAMES E. GOTTESMAN ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Carcinoma In Situ ◽  
Transitional Cell ◽  
Bacillus Calmette Guerin ◽  
Carcinoma Of The Bladder

Bacillus Calmette–Guérin (BCG) Immunotherapy for Recurrent Noninvasive Transitional Cell Carcinoma of the Bladder

2021 ◽  
pp. 135-140
Author(s):  
Vikram M. Narayan
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Carcinoma In Situ ◽  
Transitional Cell ◽  
High Grade ◽  
Bacillus Calmette Guerin ◽  
Urothelial Cell Carcinoma ◽  
Carcinoma Of The Bladder ◽  
Disease Specific

This study summarizes the landmark study assessing the value of maintenance intravesical Bacillus Calmette Guerin (BCG) to reduce the risk for recurrence or progression of high-grade superficial or carcinoma in situ (CIS) transitional cell carcinoma of the bladder. The trial randomized patients with completely resected noninvasive urothelial cell carcinoma at high risk of recurrence to BCG induction alone versus BCG induction plus maintenance therapy in the form of six weekly treatments. The study found that maintenance BCG reduces disease-specific recurrence and may also reduce the rate of disease progression.

Cyclooxygenase-2 is Highly Expressed in Carcinoma in Situ and T1 Transitional Cell Carcinoma of the Bladder

2003 ◽  
Vol 169 (3) ◽  
pp. 938-942 ◽  
Author(s):  
SHAHROKH F. SHARIAT ◽  
JA-HONG KIM ◽  
GUSTAVO E. AYALA ◽  
KIMBERLY KHO ◽  
THOMAS M. WHEELER ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Carcinoma In Situ ◽  
Transitional Cell ◽  
Cyclooxygenase 2 ◽  
Carcinoma Of The Bladder

Hypermethylation of an E-Cadherin ( CDH 1) Promoter Region in High Grade Transitional Cell Carcinoma of the Bladder Comprising Carcinoma In Situ

2003 ◽  
Vol 169 (4) ◽  
pp. 1541-1545 ◽  
Author(s):  
YOHEI HORIKAWA ◽  
KOKICHI SUGANO ◽  
MASANORI SHIGYO ◽  
HIDENOBU YAMAMOTO ◽  
MASAAKI NAKAZONO ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Promoter Region ◽  
Carcinoma In Situ ◽  
Transitional Cell ◽  
High Grade ◽  
Carcinoma Of The Bladder ◽  
E Cadherin

NBI-assisted cystoscopy to improve follow-up of patients with transitional cell carcinoma of the bladder.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 400-400
Author(s):  
Andreas Eisenhardt ◽  
Lucas Hirner ◽  
Herbert Ruebben
Keyword(s):  
Bladder Cancer ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Narrow Band Imaging ◽  
Transitional Cell ◽  
White Light Endoscopy ◽  
Second Look ◽  
Number Of Patients ◽  
Carcinoma Of The Bladder

400 Background: Narrow Band Imaging (NBI) is a new technique of urethrocystoscopy, in which only a certain bandwidths of illumination (415 (blue) and 540nm (green)) of the spectrum is used to detect urothelial carcinoma. The aim of the investigation was to analyse the potential benefit of NBI in the follow up of patients with transitional cell carcinoma of the bladder. Methods: In the time between August 2013 until August 2014, patients with history of transitional cell carcinoma of the bladder, who presented for follow-up cystoscopy , were either examined via flexible white light endoscopy [WLE] plus second look WLE (n = 317, controls) or second look NBI-cystoscopy alone (n = 308) in the same session. Results: Rates of recurrences were similiar in both groups (NBI 95 (25%); WLE 85 (26.8%)). NBI after WLE identified more tumours in 21 patients (6.1 vs. 3.81). In 9 patients NBI showed no vascularization in suspicious areas. In the control arm, in 9 cases more tumours (4,67 vs. 3.33) were identified in the second WLE. After macroscopical identification of a recurrence, the time since the last resection was measured (WLE 10,67 months, NBI 16,85 months). Conclusions: While the number of patients with recurrent bladder cancer is not influenced by the use of NBI, the additional use of NBI in the follow-up cystoscopy of patients after transurethral resection of superficial bladder cancer (TUR) leads to an increased number of detected tumors. A part of the additionally detected tumors can be explained by the double examination. In addition NBI appears to provide a hint in individual cases whether a TUR is necessary at all.

Sign in / Sign up

Export Citation Format

Share Document